X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (27879) 27879
Publication (1275) 1275
Newsletter (446) 446
Book Review (80) 80
Newspaper Article (52) 52
Book Chapter (45) 45
Magazine Article (44) 44
Dissertation (20) 20
Conference Proceeding (10) 10
Transcript (4) 4
Web Resource (3) 3
Reference (2) 2
Trade Publication Article (2) 2
Book / eBook (1) 1
Data Set (1) 1
Government Document (1) 1
Journal / eJournal (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (22729) 22729
female (13694) 13694
male (13629) 13629
vincristine - administration & dosage (11712) 11712
antineoplastic combined chemotherapy protocols - therapeutic use (11655) 11655
middle aged (9273) 9273
adult (8953) 8953
oncology (7560) 7560
cyclophosphamide - administration & dosage (7484) 7484
vincristine - therapeutic use (7284) 7284
vincristine (6946) 6946
aged (6829) 6829
doxorubicin - administration & dosage (6764) 6764
chemotherapy (5446) 5446
prednisone - administration & dosage (5230) 5230
index medicus (5160) 5160
adolescent (4689) 4689
cyclophosphamide - therapeutic use (4297) 4297
child (3943) 3943
hematology (3746) 3746
treatment outcome (3669) 3669
prognosis (3602) 3602
combined modality therapy (3546) 3546
antineoplastic combined chemotherapy protocols - administration & dosage (3534) 3534
prednisone - therapeutic use (3530) 3530
cancer (3351) 3351
doxorubicin - therapeutic use (3210) 3210
animals (3200) 3200
antineoplastic combined chemotherapy protocols - adverse effects (2979) 2979
child, preschool (2969) 2969
vincristine - adverse effects (2961) 2961
methotrexate - administration & dosage (2559) 2559
drug therapy, combination (2516) 2516
vincristine - pharmacology (2487) 2487
remission induction (2236) 2236
cyclophosphamide (2213) 2213
etoposide - administration & dosage (2181) 2181
retrospective studies (2046) 2046
follow-up studies (2031) 2031
doxorubicin (2005) 2005
neoplasm staging (1982) 1982
rituximab (1980) 1980
infant (1962) 1962
lymphoma, large b-cell, diffuse - drug therapy (1876) 1876
lymphoma, non-hodgkin - drug therapy (1868) 1868
bleomycin - administration & dosage (1854) 1854
time factors (1854) 1854
disease-free survival (1818) 1818
antineoplastic agents - therapeutic use (1767) 1767
survival rate (1756) 1756
therapy (1751) 1751
hodgkin disease - drug therapy (1661) 1661
aged, 80 and over (1623) 1623
mice (1587) 1587
lymphomas (1551) 1551
cyclophosphamide - adverse effects (1540) 1540
drug administration schedule (1523) 1523
procarbazine - administration & dosage (1508) 1508
survival analysis (1507) 1507
methotrexate - therapeutic use (1472) 1472
doxorubicin - adverse effects (1424) 1424
pediatrics (1414) 1414
prednisolone - administration & dosage (1411) 1411
survival (1372) 1372
care and treatment (1362) 1362
cisplatin - administration & dosage (1310) 1310
children (1247) 1247
radiotherapy (1245) 1245
prednisone - adverse effects (1234) 1234
cytarabine - administration & dosage (1215) 1215
non-hodgkins-lymphoma (1206) 1206
antineoplastic agents - administration & dosage (1199) 1199
lung neoplasms - drug therapy (1178) 1178
pharmacology & pharmacy (1154) 1154
dose-response relationship, drug (1101) 1101
drug resistance (1037) 1037
prednisone (1037) 1037
clinical trials as topic (1035) 1035
antineoplastic combined chemotherapy protocols (1034) 1034
lymphoma (1018) 1018
young adult (1014) 1014
prospective studies (985) 985
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (965) 965
risk factors (965) 965
dactinomycin - administration & dosage (954) 954
dexamethasone - administration & dosage (943) 943
research (942) 942
antineoplastic agents - pharmacology (941) 941
leukemia (938) 938
medicine & public health (937) 937
tumors (937) 937
lymphoma - drug therapy (934) 934
expression (917) 917
recurrence (909) 909
lymphoma, large b-cell, diffuse - pathology (899) 899
etoposide (879) 879
leukemia, lymphoid - drug therapy (875) 875
medicine, general & internal (861) 861
antibodies, monoclonal, murine-derived (858) 858
vinblastine (845) 845
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (23974) 23974
Japanese (1206) 1206
German (839) 839
French (590) 590
Chinese (475) 475
Spanish (337) 337
Russian (318) 318
Polish (238) 238
Italian (237) 237
Portuguese (38) 38
Dutch (34) 34
Hungarian (32) 32
Danish (23) 23
Hebrew (21) 21
Czech (19) 19
Korean (17) 17
Croatian (13) 13
Serbian (12) 12
Turkish (11) 11
Swedish (9) 9
Norwegian (8) 8
Romanian (8) 8
Ukrainian (7) 7
Bulgarian (5) 5
Finnish (5) 5
Slovak (4) 4
Lithuanian (2) 2
Arabic (1) 1
Bosnian (1) 1
Icelandic (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BioDrugs, ISSN 1173-8804, 01/2013, Volume 27, Issue 1, p. 69
Journal Article
International Journal of Nanomedicine, ISSN 1176-9114, 04/2015, Volume 10, pp. 3081 - 3095
Journal Article
BLOOD, ISSN 0006-4971, 07/2019, Volume 134, Issue 3, pp. 221 - 222
In this issue of Blood, Ferreri et al report preliminary results from the INGRID trial regarding the feasibility and safety of using engineered tumor necrosis... 
HEMATOLOGY | CYCLOPHOSPHAMIDE | VINCRISTINE | DOXORUBICIN
Journal Article
Biomaterials, ISSN 0142-9612, 2011, Volume 32, Issue 23, pp. 5524 - 5533
Abstract Multifunctional nanoassemblies (MNAs) were successfully developed for controlled delivery of water-soluble cationic vincristine sulfate (VCR) to... 
Advanced Basic Science | Dentistry | P-glycoprotein | Vincristine sulfate | Multifunctional nanoassemblies (MNAs) | Cellular uptake | Pharmacokinetics | Multidrug resistance | SYSTEM | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | RETENTION | DOXORUBICIN | CARRIERS | BREAST-CANCER CELLS | INHIBITION | THERAPY | LOADED NANOPARTICLES | PHOSPHATIDYLSERINE | LIPID HYBRID NANOPARTICLES | Vincristine - pharmacology | Nanoparticles - chemistry | Rats, Wistar | Drug Resistance, Multiple | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Biological Availability | Drug Resistance, Neoplasm | Male | Polyethylene Glycols - chemistry | Vincristine - metabolism | Tissue Distribution | Lecithins - chemistry | Vincristine - chemistry | Inhibitory Concentration 50 | Vincristine - administration & dosage | Vincristine - pharmacokinetics | Microscopy, Electron, Transmission | Lactic Acid - chemistry | Endocytosis - drug effects | Phosphatidylserines - chemistry | Rats | Static Electricity | Endocytosis - physiology | Particle Size | Animals | Models, Biological | Polyglycolic Acid - chemistry | Cell Line, Tumor | Calorimetry, Differential Scanning | Cell Proliferation - drug effects | Drug Delivery Systems - methods | Phosphatidylethanolamines - chemistry | Transition Temperature | Antimitotic agents | Drug resistance in microorganisms | Clathrin | Biological products | Surface active agents | Sulfates | Antineoplastic agents
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Summary Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of... 
Internal Medicine | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | II MULTICENTER | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | COMBINATION | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 12/2007, Volume 49, Issue 7, pp. 928 - 940
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 196 - 206
Summary Background Post-transplantation lymphoproliferative disorder (PTLD) develops in 1–10% of transplant recipients and can be Epstein–Barr virus (EBV)... 
Hematology, Oncology and Palliative Medicine | SOLID-ORGAN TRANSPLANTATION | DISTINCT ENTITY | VIRAL LOAD | ONCOLOGY | IMMUNOSUPPRESSION | DISEASE | LYMPHOMA | SINGLE-CENTER | II TRIAL | RECIPIENTS | EPSTEIN-BARR-VIRUS | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Organ Transplantation - pathology | Cyclophosphamide - therapeutic use | Epstein-Barr Virus Infections - therapy | Vincristine - administration & dosage | Adult | Female | Herpesvirus 4, Human - pathogenicity | Prednisolone - therapeutic use | France | Lymphoproliferative Disorders - etiology | Doxorubicin - administration & dosage | Antigens, CD20 - immunology | Rituximab | Lymphoproliferative Disorders - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Organ Transplantation - adverse effects | Adolescent | Vincristine - therapeutic use | Epstein-Barr Virus Infections - diagnosis | Lymphoproliferative Disorders - drug therapy | Aged | Germany | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Organ transplant recipients | Clinical trials | Product development | Epstein-Barr virus | Universities and colleges | Prednisolone | Cancer | Antibodies, Monoclonal, Murine-Derived | Antigens, CD20 | Lymphoproliferative Disorders | Antineoplastic Combined Chemotherapy Protocols | Organ Transplantation | Vincristine | Doxorubicin | Herpesvirus 4, Human | Life Sciences | Immunology | Epstein-Barr Virus Infections
Journal Article
Journal of Pharmaceutical Sciences, ISSN 0022-3549, 07/2011, Volume 100, Issue 7, pp. 2835 - 2848
The purpose of this study is to develop novel stable PEGylated liposome vincristine formulations with optimal antitumor efficacy. Vincristine could interact... 
drug targeting | toxicity | circulation time | drug loading | vincristine | liposomes | pharmacokinetics | complexation | sulfobutyl ether cyclodextrin | efficacy | Complexation | Sulfobutyl ether cyclodextrin | Toxicity | Drug targeting | Efficacy | Drug loading | Liposomes | Circulation time | Pharmacokinetics | Vincristine | CHEMISTRY, MEDICINAL | STERICALLY STABILIZED LIPOSOMES | ENCAPSULATED VINCRISTINE | DOXORUBICIN | PHOSPHOLIPIDS | NEUROTOXICITY | CHEMISTRY, MULTIDISCIPLINARY | STEALTH LIPOSOMES | POLY(ETHYLENE GLYCOL) | INJECTION | PHARMACOLOGY & PHARMACY | MICE | Injections, Intravenous | Models, Chemical | Male | Polyethylene Glycols - chemistry | Drug Carriers | Antineoplastic Agents, Phytogenic - administration & dosage | Vincristine - chemistry | Drug Compounding | Vincristine - administration & dosage | Female | Mice, Inbred DBA | Antineoplastic Agents, Phytogenic - pharmacokinetics | Prostatic Neoplasms - drug therapy | Vincristine - pharmacokinetics | Prostatic Neoplasms - pathology | Drug Stability | Mice, Inbred C57BL | Vincristine - toxicity | Solubility | Antineoplastic Agents, Phytogenic - chemistry | Technology, Pharmaceutical - methods | Chemistry, Pharmaceutical | Antineoplastic Agents, Phytogenic - toxicity | Maximum Tolerated Dose | Animals | beta-Cyclodextrins - chemistry | Analysis of Variance | Tumor Burden - drug effects | Cell Line, Tumor | Vincristine - analogs & derivatives | Mice | Kinetics | Delayed-Action Preparations | Phosphatidylethanolamines - chemistry | Index Medicus
Journal Article